Tetrahydrocurcumin (THC, 'White Curcumin')

Curcuma longa (reduced metabolite)
Evidence Level
Limited
2 Clinical Trials
4 Documented Benefits
2/5 Evidence Score

Tetrahydrocurcumin (THC) — often called 'white curcumin' — is the colorless reduced metabolite of curcumin, generated in vivo by gut microbiota and intestinal enzymes that hydrogenate curcumin's two C=C double bonds, and also produced commercially via hydrogenation for direct supplement use. Preclinical work in diabetic and inflammatory models suggests THC retains and in some cases enhances curcumin's antioxidant activity while being more chemically stable and water-compatible than the parent compound. Despite frequent marketing claims about THC's superiority, the human clinical evidence base remains thin compared with standard curcumin or with branded bioavailability-enhanced curcumins, and most supporting data are preclinical. Honest positioning treats THC as a mechanistically interesting reduced metabolite with promising in vitro and animal data but limited human trial evidence.

Studied Dose Human dosing for direct THC supplementation is not well established. Preclinical and supplement literature commonly references 100–500 mg/day equivalents, though robust human dose-finding RCTs are lacking.
Active Compound Tetrahydrocurcumin — the colorless, fully reduced metabolite of curcumin (hexahydroxylated chain saturated at both olefinic bonds); produced in vivo by gut microbiota or commercially via hydrogenation.

Benefits

Supports antioxidant defense (preclinical)

Tetrahydrocurcumin has been associated with strong free-radical scavenging activity and induction of endogenous antioxidant enzymes in preclinical models, including in streptozotocin-nicotinamide diabetic rat models, supporting an antioxidant-positioned ingredient. Human trial data are sparse.

Supports anti-inflammatory pathways (preclinical)

Preclinical comparisons of curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin, and turmerones report that THC differentially regulates anti-inflammatory and anti-proliferative responses, supporting a complementary anti-inflammatory positioning relative to standard curcumin.

Improved chemical stability versus curcumin

THC is colorless, more chemically stable, and more water-compatible than the parent curcumin molecule, which degrades at physiological pH. This stability advantage is a formulation-level rationale for direct supplementation rather than a confirmed clinical advantage.

May support liver and metabolic function (preclinical)

Tetrahydrocurcumin has been studied in preclinical diabetic and metabolic models for effects on glucose handling, lipid metabolism, and hepatic antioxidant status. Translation to robust human outcomes remains an active area of investigation.

Mechanism of action

1

Free-radical scavenging by reduced beta-diketone

The saturated beta-diketone in tetrahydrocurcumin retains hydrogen-donating capacity for direct radical scavenging while removing the conjugated olefinic system of curcumin, contributing to a distinctive antioxidant profile demonstrated in preclinical models.

2

Modulation of inflammatory transcription factors

Preclinical studies show THC modulates NF-κB and other inflammatory transcription factors and downstream cytokines such as TNF-α and IL-6, contributing to its observed anti-inflammatory profile relative to other curcuminoids in cell-based work.

3

Endogenous gut metabolite of curcumin

THC is the major in vivo reductive metabolite of curcumin generated by gut microbiota and intestinal enzymes; some of curcumin's clinical effects may in fact be mediated by THC formed enterically, motivating interest in direct THC supplementation.

Clinical trials

1
Tetrahydrocurcumin in Streptozotocin-Nicotinamide Diabetic Rats — Antioxidant Effects

Preclinical study in streptozotocin-nicotinamide induced diabetic rats evaluating the antioxidant effects of tetrahydrocurcumin on lipid peroxidation and antioxidant enzyme activity.

Streptozotocin-nicotinamide diabetic rat model; preclinical.

Tetrahydrocurcumin reduced lipid peroxidation and improved antioxidant enzyme activity in diabetic rats, supporting an antioxidant role for THC in metabolic stress. Preclinical evidence — direct human RCT translation is limited.

2
Differential Anti-Inflammatory Action of Curcuminoids and Turmerones

Mechanistic comparison of curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin, and turmerones on anti-inflammatory and anti-proliferative responses through ROS-independent mechanisms.

Cell-based mechanistic study; preclinical.

Curcumin and its analogs including tetrahydrocurcumin differentially regulate anti-inflammatory and anti-proliferative responses through ROS-independent mechanisms, supporting THC's distinctive role within the curcuminoid family.

Side effects and drug interactions

Common Potential side effects

Limited human clinical safety data specific to direct tetrahydrocurcumin supplementation.
Generally well tolerated in preclinical models at studied doses.
Mild gastrointestinal discomfort possible by analogy to curcumin.
Theoretical caution in active gallbladder disease, mirroring curcumin.
Not extensively studied in pregnancy, lactation, or pediatric populations.

Important Drug interactions

Anticoagulants and antiplatelet drugs (warfarin, clopidogrel) — theoretical platelet effects by analogy to curcumin; monitor.
Antidiabetic medications (insulin, sulfonylureas) — theoretical additive glucose-lowering effects; monitor blood sugar.
CYP-substrate medications — limited human pharmacokinetic data; discuss combined use with clinician.
High-dose curcumin or other curcuminoid products — overlapping mechanism; combine cautiously.

Frequently asked questions about Tetrahydrocurcumin (THC, 'White Curcumin')

What is the recommended dosage of Tetrahydrocurcumin (THC, 'White Curcumin')?

The clinically studied dose for Tetrahydrocurcumin (THC, 'White Curcumin') is Human dosing for direct THC supplementation is not well established. Preclinical and supplement literature commonly references 100–500 mg/day equivalents, though robust human dose-finding RCTs are lacking.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Tetrahydrocurcumin (THC, 'White Curcumin') used for?

Tetrahydrocurcumin (THC, 'White Curcumin') is studied for supports antioxidant defense (preclinical), supports anti-inflammatory pathways (preclinical), improved chemical stability versus curcumin. Tetrahydrocurcumin has been associated with strong free-radical scavenging activity and induction of endogenous antioxidant enzymes in preclinical models, including in streptozotocin-nicotinamide diabetic rat models, supporting an antioxidant-positio…

Are there side effects from taking Tetrahydrocurcumin (THC, 'White Curcumin')?

Reported potential side effects may include: Limited human clinical safety data specific to direct tetrahydrocurcumin supplementation. Generally well tolerated in preclinical models at studied doses. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does Tetrahydrocurcumin (THC, 'White Curcumin') interact with medications?

Known drug interactions may include: Anticoagulants and antiplatelet drugs (warfarin, clopidogrel) — theoretical platelet effects by analogy to curcumin; monitor. Antidiabetic medications (insulin, sulfonylureas) — theoretical additive glucose-lowering effects; monitor blood sugar. Consult a pharmacist or healthcare provider if you take prescription medications.

Is Tetrahydrocurcumin (THC, 'White Curcumin') good for antioxidant?

Yes, Tetrahydrocurcumin (THC, 'White Curcumin') is researched for Antioxidant support. Tetrahydrocurcumin has been associated with strong free-radical scavenging activity and induction of endogenous antioxidant enzymes in preclinical models, including in streptozotocin-nicotinamide diabetic rat models, supporting an antioxidant-positioned ingredient.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Murugan P, Pari L. Antioxidant effect of tetrahydrocurcumin in streptozotocin-nicotinamide induced diabetic rats. Life Sci. 2006;79(18):1720-8. doi: 10.1016/j.lfs.2006.06.001.PubMedUsed to support: Foundational preclinical study — tetrahydrocurcumin reduced lipid peroxidation and improved antioxidant enzyme activity in streptozotocin-nicotinamide diabetic rats, supporting THC's antioxidant role in metabolic stress. Preclinical only; not a human RCT.
  2. Sandur SK, Pandey MK, Sung B, Ahn KS, Murakami A, Sethi G, Limtrakul P, Badmaev V, Aggarwal BB. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis. 2007;28(8):1765-73. doi: 10.1093/carcin/bgm123.PubMedUsed to support: Mechanistic preclinical comparison — curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin, and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through ROS-independent mechanisms. Cell-based work; underpins THC's distinct anti-inflammatory profile within the curcuminoid family.
  3. Murugan P, Pari L. Influence of tetrahydrocurcumin on erythrocyte membrane bound enzymes and antioxidant status in experimental type 2 diabetic rats. J Ethnopharmacol. 2007;113(3):479-86. doi: 10.1016/j.jep.2007.07.004.PubMedUsed to support: Follow-up preclinical study — tetrahydrocurcumin influenced erythrocyte membrane-bound enzymes and antioxidant status in experimental type 2 diabetic rats. Reinforces antioxidant positioning under metabolic stress; preclinical only.